<DOC>
	<DOCNO>NCT00918164</DOCNO>
	<brief_summary>The purpose study estimate bioavailability PF-04457845 tablet relative solution evaluate effect food ( fast vs. high fat meal ) pharmacokinetics oral tablet formulation PF-04457845</brief_summary>
	<brief_title>Evaluation Of The Relative Bioavailability Of PF-04457845 Tablet To Solution Formulation And Food Effect In Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male subject healthy female subject nonchild bear potential . ( Healthy define clinically relevant abnormality identify detailed medical history , complete physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) ; Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) ; Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect trial ; Willing able comply schedule visit , treatment plan , laboratory test , trial procedure ; Willing able consume nonvegetarian highfat meal . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) ; History febrile illness within 5 day prior first dose ; Any condition possibly affect drug absorption ( eg , gastrectomy ) ; A positive urine drug screen ; History regular alcohol consumption exceed 7 drinks/week female 14 drinks/week men ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen ; Treatment investigational drug within 30 day 5 halflives ( determined local requirement , whichever long ) precede first dose trial medication ; 12lead ECG demonstrate QTc &gt; 450 msec screening . If QTc exceed 450 msec , ECG repeat two time average three QTc value use determine subject 's eligibility ; Pregnant nursing female females childbearing potential ; Use prescription nonprescription drug , vitamin dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose trial medication ; Herbal supplement hormone replacement therapy must discontinue 28 day prior first dose trial medication . Other exception may grant qualified member Pfizer study management ; Unwillingness refrain consumption grapefruit/pomelo grapefruit/pomelocontaining product 7 day prior first dose study medication completion followup visit . Blood donation approximately 1 unit ( ~500 mL ) within 56 day prior dose ; Unwillingness inability comply Lifestyle guideline ; Subject Investigator subInvestigator , research assistant , pharmacist , study coordinator , staff , relative study personnel directly involve conduct study ; Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate trial participation investigational product administration may interfere interpretation trial result , judgment investigator , would make subject inappropriate entry trial .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>